PTSD Trial, Recruiting NCT05895006 Sponsor: The University of Texas Health Science Center, Houston Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT05895006
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are right-handed
  • People who have normal vision or vision that is fully corrected with glasses or contact lenses, and a normal sense of smell
  • People between the ages of 18 and 50 years
  • People who pass a safety screening checklist for the brain stimulation method used in this trial, which includes things like not having a serious head injury history (confirm with trial site for full list)
  • For patients: People who have been diagnosed with PTSD
  • For patients who take psychiatric or mood-related medications: People whose medication dose has been stable for at least the past 2 months
  • People who, if they occasionally use substances or have a mild substance use disorder (patients only), are able to stop use for at least 48 hours before their appointment

Who may not be able to join:

  • People who have a history of a serious medical illness, such as cancer, metabolic syndrome, heart disease, or inflammatory conditions, or a neurological condition such as epilepsy, stroke, or Parkinson's disease
  • For patients: People who have a diagnosis of another major mental health condition at the same time, although depression, anxiety, and mild substance use disorder are allowed given how commonly they occur alongside PTSD
  • For healthy volunteers (non-patients): People who have a history of any major mental health diagnosis, or who are currently taking any medications that affect mood or brain function
  • People who are in severe psychiatric crisis, including anyone who is actively at risk of harming themselves or others
  • People who have had a head injury that caused them to lose consciousness for more than 5 minutes
  • People who regularly drink three or more alcoholic drinks per day
  • People who are unable to stop using substances — including alcohol, nicotine, cannabis, amphetamines, narcotics, cocaine, hallucinogens, tranquilisers, barbiturates, solvents, or sleep medications — for 48 hours before their scan
  • People who take certain blood pressure medications known as calcium channel blockers (such as verapamil or nifedipine) or alpha-blockers (such as prazosin or terazosin) and are unable to pause these for 48 hours before scanning
  • People who do not pass a urine drug screening test conducted before the study, which checks for a range of substances including alcohol, amphetamines, benzodiazepines, cocaine, marijuana, and opiates
  • People who are pregnant, as confirmed by a urine test, because the safety of MRI scanning for unborn babies has not been established
  • People who have any implanted devices that are electrically, magnetically, or mechanically activated — such as a cardiac pacemaker — because the MRI equipment may interfere with how those devices work

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wen Li, PhD, The University of Texas Health Science Center, Houston

Phone: (713) 486-2700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 April 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in neural oscillatory activity as assessed by electroencephalogram (EEG) alpha power change; Change in cortical activity as assessed by functional magnetic resonance imaging (fMRI) blood-oxygen-level dependent (BOLD) signal change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov